EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dapagliflozin Alleviates High-Fat-Induced Obesity Cardiomyopathy by Inhibiting Ferroptosis

Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Di Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Zhongshan Hospital of Dalian University, Dalian, China. Hauptthemen laut MEDLINE: Ferroptosis, Glucosides, Obesity, Benzhydryl Compounds. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear. Ferroptosis is an iron dependent form of cell death and has been proved to be an important role in heart failure. The aim of this study is to determine whether Dapa improves obesity-related heart failure by regulating ferroptosis in high-fat diet rats. Methods and results: Male SD rats were fed a high-fat diet for 12 weeks and confirmed of obese heart failure by metabolic parameters and cardiac ultrasound. Being overweight by 20% compared with the normal group, with elevated systolic blood pressure and abnormal levels of insulin and blood lipid (TG and LDL-c), is recognized as obesity. The obese rats with reduced EF, FS, and E/A shown on ultrasound are defined as the obese heart failure (OHF) group. Histological tests confirmed the more pronounced cardiac fibrosis, mitochondrial volume and collagen deposition in OHF group. Dapa treatment effectively reduced body weight, INS, ISI/IRI index, TG and HDL-C levels (P < 0.05). Also, Dapa administration can slightly decrease the SBP and DBP levels; however, there was no statistical difference among those four groups. Furthermore, Dapa treatment can significantly improve high-fat induced systolic and diastolic dysfunction via regulating cardiac histological abnormalities, including less obvious mitochondrial swelling, muscle fibre dissolution and collagen deposition. Additionally, genes from the OHF group were used by GO enrichment analysis, and it shows that ferroptosis metabolic pathway participated in the development of obese phenotype of heart failure. More importantly, Dapa significantly inhibited Fe2+ and MDA levels (P < 0.05), but augmented GSH content (P < 0.05). In addition, the mRNAs and protein expression of some important regulators of ferroptosis, like GPX4, SLC7A11, FTH1 and FPN1, were all decreased after Dapa intervention.

Conclusion

Dapa improved high-fat induced obese cardiac dysfunction via regulating ferroptosis pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisGlucosidesObesityBenzhydryl CompoundsCardiomyopathiesAnimalsRatsMaleDiet, High-FatRats, Sprague-DawleyDisease Models, AnimalSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

DapagliflozinFerroptosisObesity‐related cardiomyopathySGLT2i

Substanzen

GlucosidesdapagliflozinBenzhydryl CompoundsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
  • Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • Yancheng No. 1 People's Hospital, Yancheng, China.
  • Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital), Dalian, China.
  • The Second Hospital of Dalian Medical University, Dalian, China.

Zitieren

APA

Chen, D., Shi, J., Wu, Y., Miao, L., Wang, Z., Wang, Y., Xu, S., & Lou, Y. (2025). Dapagliflozin Alleviates High-Fat-Induced Obesity Cardiomyopathy by Inhibiting Ferroptosis. ESC Heart Failure. https://doi.org/10.1002/ehf2.15150

Vancouver

Chen D, Shi J, Wu Y, Miao L, Wang Z, Wang Y, et al. Dapagliflozin Alleviates High-Fat-Induced Obesity Cardiomyopathy by Inhibiting Ferroptosis. ESC Heart Failure. 2025. doi:10.1002/ehf2.15150

BibTeX
@article{Chen2025,
  author = {Chen, Di and Shi, Jiahao and Wu, Yue and Miao, Lizhu and Wang, Zilin and Wang, Yixuan and Xu, Siwei and Lou, Yu},
  title = {Dapagliflozin Alleviates High-Fat-Induced Obesity Cardiomyopathy by Inhibiting Ferroptosis},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15150}
}
Kostenlos starten →